Geisinger Health System (GHS) is an integrated, comprehensive health care delivery system that serves a large, stable, mainly rural population in north central and northeastern Pennsylvania. Geisinger has a fully functional and integrated electronic medical record (EMR) system, and is a recognized leader in the use of EMR and health information technology. GHS has received national accolades for its commitment to developing and testing information technology-enabled innovations in health care delivery. Geisinger's infrastructure and experience in this area provide a paradigm for incorporating genomic data into clinical care. To leverage the health system's assets for genomic medicine Geisinger launched an innovative biobanking program, the MyCode project that is creating a large, central repository of patient samples (blood, DNA, serum and tissue) that are linkable to data in the Geisinger EMR for broad research use in a manner that protects confidentiality of patient information. More than 30,000 Geisinger patients have consented to participate in the biobanking program. The EMR-linked biospecimen bank is being used for genomic research in cardiovascular disease, obesity, cancer, and other disorders with significant public health impact. Through this application GHS is seeking inclusion in the eMERGE Phase II.
The specific aims of this Geisinger eGenomic Medicine (GeM) program are to: 1) use existing biospecimens and EMR- generated phenotypes (ePhenotypes) to identify genetic variants associated with increased disease risk or altered treatment response;proposed new ePhenotypes are extreme obesity and related conditions, abdominal aortic aneurysm, and weight gain induced by anti-psychotic drugs;2) develop and test approaches to provide clinically relevant genetic research results to patients and clinical providers;and 3) study sociocultural concerns of patients residing in rural areas regarding Genomic Medicine research. Participation in eMERGE Phase II will substantially accelerate Geisinger's goal of using its integrated health care system, stable patient population, and advanced EMR capabilities to drive Personalized Health Care.

Public Health Relevance

The integration of genomic data into clinical practice is a necessary step in the adoption of Personalized Medicine;electronic medical record data have enormous potential to accelerate this process. Geisinger has a unique combination of resources and experience that make it an ideal setting for both the discovery and application phases of genomic medicine research and integration of genomic data into clinical care.

National Institute of Health (NIH)
National Human Genome Research Institute (NHGRI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel ()
Program Officer
Li, Rongling
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Geisinger Clinic
United States
Zip Code
Sun, Xiangqing; Lu, Qing; Mukherjee, Shubhabrata et al. (2014) Analysis pipeline for the epistasis search - statistical versus biological filtering. Front Genet 5:106
Rasmussen, Luke V; Thompson, Will K; Pacheco, Jennifer A et al. (2014) Design patterns for the development of electronic health record-driven phenotype extraction algorithms. J Biomed Inform 51:280-6
Jarvik, Gail P; Amendola, Laura M; Berg, Jonathan S et al. (2014) Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet 94:818-26
Patel, Zubin H; Kottyan, Leah C; Lazaro, Sara et al. (2014) The struggle to find reliable results in exome sequencing data: filtering out Mendelian errors. Front Genet 5:16
Kullo, Iftikhar J; Haddad, Ra'ad; Prows, Cynthia A et al. (2014) Return of results in the genomic medicine projects of the eMERGE network. Front Genet 5:50
Muthalagu, A; Pacheco, J A; Aufox, S et al. (2014) A rigorous algorithm to detect and clean inaccurate adult height records within EHR systems. Appl Clin Inform 5:118-26
Muir, A J; Gong, L; Johnson, S G et al. (2014) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-*-based regimens. Clin Pharmacol Ther 95:141-6
Brothers, Kyle B; Lynch, John A; Aufox, Sharon A et al. (2014) Practical guidance on informed consent for pediatric participants in a biorepository. Mayo Clin Proc 89:1471-80
Kuivaniemi, Helena; Ryer, Evan J; Elmore, James R et al. (2014) Update on abdominal aortic aneurysm research: from clinical to genetic studies. Scientifica (Cairo) 2014:564734
Williams, Janet L; Faucett, W Andrew; Smith-Packard, Bethanny et al. (2014) An assessment of time involved in pre-test case review and counseling for a whole genome sequencing clinical research program. J Genet Couns 23:516-21

Showing the most recent 10 out of 18 publications